glp 1 induced pancreatitis GLP-1 Agonists and Risk GLP-1 | Pancreapedia

New research published today in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonistsdrugs commonly used to treat obesity and diabetesand better outcomes among breast cancer patients

Disease Prevention & Management Beyond reducing the risks of heart disease, GLP-1 RAs have also been explored for prevention and managing: 12 Chronic kidney disease (CKD) Neurological diseases, including Alzheimer's and Parkinson's diseases Non-alcoholic fatty liver disease (NAFLD) Polycystic ovary syndrome (PCOS) And this list is likely just be the beginning, as overweight and obese individuals are at significant risk of many serious health conditions like cancer and depression

AHA Journals+1 A new twist: statins, the microbiome, bile acids and lower GLP-1 In 2024, a high-quality translational study reported that statins can aggravate insulin resistance by reducing circulating active GLP-1 levels and that the effect appears to be microbiome-dependent

This combination is different from semaglutide and tirzepatide

From a regulatory and classification perspective , tirzepatide represents a distinct therapeutic class